Trevi Therapeutics
Business Services · Connecticut, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
195 Church St Fl 14, New Haven, Connecti...Phone Number
(203) 304-2499Website
www.trevitherapeutics.comRevenue
$52.8 MillionStock Symbol
TRVIIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
2
1
About Trevi Therapeutics
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for patients living with serious chronic conditions that have limited treatment options. The company concentrates on developing novel medicines designed to address diseases associated with chronic cough and other conditions involving neurological and sensory pathways.Explore more
Trevi Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Trevi Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Trevi Therapeutics is spiking on competitors!
Earning: See what the market has to say on Trevi Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Trevi Therapeutics
Click to see if Trevi Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Trevi Therapeutics has new funding data
Product Launch: Get notified when Trevi Therapeutics launches new products
Check if Trevi Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Trevi Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Trevi Therapeutics
Find 3 more new buyers
Compare Similar Companies to Trevi Therapeutics
Compare insights from companies similar to Trevi Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Trevi Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Trevi Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Trevi Therapeutics.
Trevi Therapeutics financials insights
Gather financial insights about Trevi Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Series A
$10M
2014
Series B
$26M
2015
Debt
$15M
2017
Series C
$50.5M
2019
Stock Offering
$55M
Share Placement
$15M
2022
Share Placement
$55M
Trevi Therapeutics Tech Stack
A closer look at the technologies used by Trevi Therapeutics
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Trevi Therapeutics has reported approximately $319 million in cash equivalents and marketable securities at the end of Q2 2026, maintaining its cash runway guidance extending into 2030, unchanged from the prior quarterly call.
Earnings, Accounting, Financial Reporting, Finance
Project
Trevi Therapeutics has submitted a meeting request to the FDA to discuss the development program for non-IPF ILD-related chronic cough, with an expected response on whether the meeting has been granted anticipated within the current month.
Product Development, Pharmaceuticals
Project
Trevi Therapeutics has announced that its planned FDA alignment meeting for the non-IPF ILD- related chronic cough program will focus on exclusion criteria specific to the non-IPF population, protocol parameters relative to the IPF protocol, and the pathway to an NDA filing for that indication.
Pharmaceuticals
Project
Clinical Operations
Trevi Therapeutics News & Media
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic coughTrevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
Conference call and webcast to be held at 4:30 p.m. ET Conference call and webcast to be held at 4:30 p.m. ETTrevi Therapeutics to Participate in Upcoming August Conferences
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in August.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Trevi Therapeutics
Sign Up For FreeTo access detailed company insights
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for patients living with serious chronic conditions that have limited treatment options. The company concentrates on developing novel medicines designed to address diseases associated with chroni... Read More
